GlassScriptPhysician profile
Joel C Shebowich
NPI 1366468902
$32,390.33
in general payments reported to CMS, 2019-2025
55 companies · $2,928 in 2025
The $2,928 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $9,229 · 2021: $3,587 · 2022: $2,005 · 2023: $2,090 · 2024: $1,577 · 2025: $2,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,992 · Travel and Lodging: $2,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,992.03 |
| Travel and Lodging | $2,602.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17,103.51 | 2019-2022 | |
| National Marrow Donor Program | $2,868.89 | 2025 | |
| Abbvie INC. | $1,744.89 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,409.79 | 2019-2024 | Farxiga, Fasenra, Airsupra |
| Amgen INC. | $1,291.43 | 2019-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $985.44 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $845.85 | 2019-2023 | |
| Lilly USA, LLC | $835.33 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $612.81 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.01 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Janssen Pharmaceuticals, INC | $452.75 | 2019-2024 | Xarelto |
| Allergan, INC. | $383.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $357.44 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $296.53 | 2019-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Grifols USA, LLC | $234.47 | 2020-2024 | Prolastin-C Liquid |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Shebowich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.